{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:31:33Z","timestamp":1791203493959,"version":"4.2.0"},"reference-count":30,"publisher":"American Diabetes Association","issue":"7","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,7,1]]},"abstract":"<jats:p>OBJECTIVE\u2014Cardiovascular disease (CVD) risk is increased in type 2 diabetes. The purpose of this study was to assess the effect of 10 mg of atorvastatin versus placebo on CVD prevention in subjects with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets.<\/jats:p>\n                  <jats:p>RESEARCH DESIGN AND METHODS\u2014Subjects were randomly assigned to receive 10 mg of atorvastatin or placebo in a 4-year, double-blind, parallel-group study. The composite primary end point comprised cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, recanalization, coronary artery bypass surgery, resuscitated cardiac arrest, and worsening or unstable angina requiring hospitalization.<\/jats:p>\n                  <jats:p>RESULTS\u2014A total of 2,410 subjects with type 2 diabetes were randomized. Mean LDL cholesterol reduction in the atorvastatin group over 4 years was 29% versus placebo (P &amp;lt; 0.0001). When we compared atorvastatin versus placebo, composite primary end point rates were 13.7 and 15.0%, respectively (hazard ratio 0.90 [95% CI 0.73\u20131.12]). In the subset of 1,905 subjects without prior myocardial infarction or interventional procedure, 10.4% of atorvastatin- and 10.8% of placebo-treated subjects experienced a primary end point (0.97 [0.74\u20131.28]). In the 505 subjects with prior myocardial infarction or interventional procedure, 26.2% of atorvastatin- and 30.8% of placebo-treated subjects experienced a primary end point (0.82 [0.59\u20131.15]). Relative risk reductions in fatal and nonfatal myocardial infarction were 27% overall (P = 0.10) and 19% (P = 0.41) and 36% (P = 0.11) for subjects without and with prior myocardial infarction or interventional procedure, respectively.<\/jats:p>\n                  <jats:p>CONCLUSIONS\u2014Composite end point reductions were not statistically significant. This result may relate to the overall study design, the types of subjects recruited, the nature of the primary end point, and the protocol changes required because of changing treatment guidelines. For these reasons, the results of the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) did not confirm the benefit of therapy but do not detract from the imperative that the majority of diabetic patients are at risk of coronary heart disease and deserve LDL cholesterol lowering to the currently recommended targets.<\/jats:p>","DOI":"10.2337\/dc05-2415","type":"journal-article","created":{"date-parts":[[2006,6,26]],"date-time":"2006-06-26T17:13:17Z","timestamp":1151341997000},"page":"1478-1485","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":449,"title":["Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes"],"prefix":"10.2337","volume":"29","author":[{"given":"Robert H.","family":"Knopp","sequence":"first","affiliation":[{"name":"Department of Medicine and the Northwest Lipid Research Clinic, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"d\u2019Emden","sequence":"additional","affiliation":[{"name":"Department of Medicine, Royal Brisbane and Women\u2019s Hospital, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan G.","family":"Smilde","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Refaja-Hospital, Stadskanaal, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[{"name":"Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ASPEN Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031219225719000_R1","doi-asserted-by":"crossref","unstructured":"Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med\u2008339: 229\u2013234, 1998","DOI":"10.1056\/NEJM199807233390404"},{"key":"2022031219225719000_R2","doi-asserted-by":"crossref","unstructured":"Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation\u2008102:1014\u20131019, 2000","DOI":"10.1161\/01.CIR.102.9.1014"},{"key":"2022031219225719000_R3","doi-asserted-by":"crossref","unstructured":"Whiteley L, Padmanabhan S, Hole D, Isles C: Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley Survey. Diabetes Care\u200828:1588\u20131593, 2005","DOI":"10.2337\/diacare.28.7.1588"},{"key":"2022031219225719000_R4","doi-asserted-by":"crossref","unstructured":"Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Type 2 diabetes as a \u201ccoronary heart disease equivalent\u201d: an 18-year prospective population-based study in Finnish subjects. Diabetes Care\u200828:2901\u20132907, 2005","DOI":"10.2337\/diacare.28.12.2901"},{"key":"2022031219225719000_R5","doi-asserted-by":"crossref","unstructured":"Lee CD, Folsom AR, Pankow JS, Brancati FL: Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation\u2008109:855\u2013860, 2004","DOI":"10.1161\/01.CIR.0000116389.61864.DE"},{"key":"2022031219225719000_R6","doi-asserted-by":"crossref","unstructured":"Evans JM, Wang J, Morris AD: Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ\u2008324:939\u2013942, 2002","DOI":"10.1136\/bmj.324.7343.939"},{"key":"2022031219225719000_R7","doi-asserted-by":"crossref","unstructured":"Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med\u2008161:1717\u20131723, 2001","DOI":"10.1001\/archinte.161.14.1717"},{"key":"2022031219225719000_R8","doi-asserted-by":"crossref","unstructured":"Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE: Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med\u2008161:242\u2013247, 2001","DOI":"10.1001\/archinte.161.2.242"},{"key":"2022031219225719000_R9","doi-asserted-by":"crossref","unstructured":"Manzato E, Zambon A, Lapolla A, Zambon S, Braghetto L, Crepaldi G, Fedele D: Lipoprotein abnormalities in well-treated type 2 diabetic patients. Diabetes Care\u200816:469\u2013475, 1993","DOI":"10.2337\/diacare.16.2.469"},{"key":"2022031219225719000_R10","doi-asserted-by":"crossref","unstructured":"Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care\u200820:614\u2013620, 1997","DOI":"10.2337\/diacare.20.4.614"},{"key":"2022031219225719000_R11","doi-asserted-by":"crossref","unstructured":"Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial: The Care Investigators. Circulation\u200898:2513\u20132519, 1998","DOI":"10.1161\/01.CIR.98.23.2513"},{"key":"2022031219225719000_R12","doi-asserted-by":"crossref","unstructured":"Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care\u200826:2713\u20132721, 2003","DOI":"10.2337\/diacare.26.10.2713"},{"key":"2022031219225719000_R13","doi-asserted-by":"crossref","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet\u2008361:2005\u20132016, 2003","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"2022031219225719000_R14","doi-asserted-by":"crossref","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet\u2008364:685\u2013696, 2004","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"2022031219225719000_R15","doi-asserted-by":"crossref","unstructured":"Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O\u2019Brien E, Ostergren J: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care\u200828:1151\u20131157, 2005","DOI":"10.2337\/diacare.28.5.1151"},{"key":"2022031219225719000_R16","doi-asserted-by":"crossref","unstructured":"Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D, for the Treating to New Targets Investigators: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care\u200829:1220\u20131226, 2006","DOI":"10.2337\/dc05-2465"},{"key":"2022031219225719000_R17","unstructured":"World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Geneva, World Health Organization, 1999"},{"key":"2022031219225719000_R18","doi-asserted-by":"crossref","unstructured":"Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem\u200818:499\u2013502, 1972","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"2022031219225719000_R19","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet\u2008366:1267\u20131278, 2005","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2022031219225719000_R20","doi-asserted-by":"crossref","unstructured":"Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P: Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations: monitoring trends and determinants in cardiovascular disease. Lancet\u2008353:1547\u20131557, 1999","DOI":"10.1016\/S0140-6736(99)04021-0"},{"key":"2022031219225719000_R21","doi-asserted-by":"crossref","unstructured":"Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA\u2008285:2486\u20132497, 2001","DOI":"10.1001\/jama.285.19.2486"},{"key":"2022031219225719000_R22","doi-asserted-by":"crossref","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA\u2008288:2998\u20133007, 2002","DOI":"10.1001\/jama.288.23.2998"},{"key":"2022031219225719000_R23","doi-asserted-by":"crossref","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d\u2019Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet\u2008366:1849\u20131861, 2005","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"2022031219225719000_R24","doi-asserted-by":"crossref","unstructured":"Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O\u2019Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet\u2008361:1149\u20131158, 2003","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"2022031219225719000_R25","doi-asserted-by":"crossref","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med\u2008350:1495\u20131504, 2004","DOI":"10.1056\/NEJMoa040583"},{"key":"2022031219225719000_R26","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA\u2008285:1711\u20131718, 2001","DOI":"10.1001\/jama.285.13.1711"},{"key":"2022031219225719000_R27","doi-asserted-by":"crossref","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med\u2008352:1425\u20131435, 2005","DOI":"10.1056\/NEJMoa050461"},{"key":"2022031219225719000_R28","doi-asserted-by":"crossref","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care\u200816:434\u2013444, 1993","DOI":"10.2337\/diacare.16.2.434"},{"key":"2022031219225719000_R29","doi-asserted-by":"crossref","unstructured":"Knopp RH: Drug treatment of lipid disorders. N Engl J Med\u2008341:498\u2013511, 1999","DOI":"10.1056\/NEJM199908123410707"},{"key":"2022031219225719000_R30","doi-asserted-by":"crossref","unstructured":"Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation\u2008110:227\u2013239, 2004","DOI":"10.1161\/01.CIR.0000133317.49796.0E"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/29\/7\/1478\/656428\/zdc00706001478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/29\/7\/1478\/656428\/zdc00706001478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T15:52:52Z","timestamp":1647100372000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/29\/7\/1478\/28617\/Efficacy-and-Safety-of-Atorvastatin-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,1]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc05-2415","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,1]]}}}